Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For years endlessly calling a company a worthless scam and buying those shares is a slimy business. God help them.
Yep it states most likely. Bears can like it or not, I loved to hear that info.
I wonder if this is one of the academic laboratories they shipped B to.
It's not IPIX so why's it linked?
Exactly. Leo's moving us along nicely.
The difference is NNVC didn't have B to go after these viruses but we do. Government labs are getting results with Brilacidin and keep ordering more. B we are finding is a broad spectrum anti-viral. A lot of clinical testing was interrupted due to covid so having an anti-viral to test gave some a chance to proceed.
There's no getting around to it since it's happening now. B has already been shipped out and besides RBL testing has been happening. Biden is putting 11 billion up for viral funding here. Them hills have lot's of government money.
So week after unblinding. Unblinding next week data comes week after is the way it's looking.
Then there are some that rehash nonsense.
It gives his apologists some material to work on, while Kip's Bay and Aspire dump some more cheap shares into the market.
Looks like someone desired for it to close red. Likely a complainer.
Looked like some tried a dump this morning and it backfired. Viral testing spoke about in todays release fits nicely into the Whitehouse strategy for national pandemic preparedness. "Develop broad-spectrum antivirals and prioritize other viral classes that present emerging threats to prevent future viral pandemics. The federal government will promote the ongoing discovery and development of antivirals with broad-spectrum activity against coronaviruses, which would potentially enable rapid preclinical testing and clinical trials if and when a new zoonotic coronavirus appears. As the program unfolds, other viral classes that represent emerging pandemic threats will also be prioritized to generate new therapeutics". Go B
Leo's out of the blue employment contract is results based. Time for those results. Go B
My thought was the expanded use here was driven by positive raw data seen in the two US hospitals that treated patients. The trial ended around the time Florida had the large outbreak.
"Based on information received from the data management and biostatistics vendors, study unblinding, analysis of the unblinded data and release of topline study results for the Brilacidin COVID-19 trial is anticipated to occur in mid-to-late October".
Unblinding and data analysis for Leo's report coming in short order.
Hopefully B does show a good level of success because with these variants cropping up Covid-19 is not tapping out any time soon.
I'm sure. Does not change my opinion statement.
It's clear now the soc isn't effective in sicker patients hence why B arm was directed to sicker cases. Effectiveness in the B arm should be crystal clear. All in my opinion.
Yep my mistake 60 Bril +soc and 60 Placebo +soc. 120 soc total. Thanks.
Wow a variant of a variant. Good results and we may just get EUA. Go B
The study design was written this way to get approved medicine to each patient due to the severity of covid-19, all patients get the approved treatment while 120 got B added. It's clear now the soc isn't effective in sicker patients hence why B arm was directed to sicker cases. Effectiveness in the B arm should be crystal clear. All in my opinion.
Prurison lab was a cave when compared to prestigious George Mason RBL.
Some are not happy with todays uptick.
Exactly. Leo just didn't walk into these hospitals with a container of B and say try this. B's MOA coupled with results got us there.
Slow trading day. There's no so called leak either way. We definitely need some good news to turn it around.
That's my take on it. Since B is already in the hospital pharmacy she would have received it the 14th which is the same day.
She was in Critical condition but has lived 6 more days since receiving Brilacidin? Is that the inference?
If so, I'm imagining B's greater positive effect on Moderate to Severe cases.
quots
Not long now before results are announced.
Possibly this being a clinical trial drug they were warned in writing not to print or report any account so not to interfere.
That Ivermectin story is rehashed old news which started Oct8. Since then on October 14th the Drocks attorney said this- But, Huxtable said, another medication that hasn’t gotten FDA approval is being used to treat COVID-19 patients. Drock signed a special release so his wife could receive the drug Brilacidin, he told Nutt.
But, unlike Ivermectin, the FDA has allowed the drug to be used in clinical trials with hospitalized COVID-19 patients.
So by this Oct 14th account she would have started Brilacidin.
https://www.palmbeachpost.com/story/news/coronavirus/2021/10/13/covid-patients-request-ivermectin-denied-hospital-lawyer-claims/8437265002/
Agree the anticipated mid to and late October timeline on record was given to Leo. We are still in mid-October range.
These are clearly all forward looking achievements i.e. Capital Appreciation. I'm thinking feedback from B has been good.
"contingent upon the achievement of certain market capitalization, licensing revenue and clinical trial performance goals, and (ii) cash awards with a maximum value of up to $14.0 million, contingent upon the achievement of certain market capitalization and licensing revenue goals".
Go B
Isn't that the truth. At this point and time Leo takes performance based incentives in the midst of trial data coming any day while simultaneously allowing B for compassionate care use. I like it.
They'll become unhinged as Leo capitalizes on those performance based incentives i.e. licensing revenue and clinical trial performance goals. Go Leo bring home those results.
Agree. Nice going btw.
Pocket money but go ahead.
Nice. Now we see performance based incentives.
It's a way but not likely right now at our low share price. This would be something for a high value company to attract small investors
A forward split in a stock would increase the outstanding share count. Something I wouldn't consider happening right now at our low share price though.
Yep looking forward to excellent news.
I look forward to see what Mr. Ehrlich and Ipix have for their planning.
That ship is taking on water. Go B make covid go away.
Leo would have performance shares award, including clinical trial results. Sounds bullish. Go B
For what I've seen current soc is not worth spit in hospitalized patients.
It may just be helping some very sick persons. If it helps it's for the good of mankind regardless of ones stance against the company.